TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
SynAct Pharma AB ( (SE:SYNACT) ) just unveiled an update.
SynAct Pharma AB has announced that Edison Investment Research Ltd., a UK-based firm, has initiated coverage of the company. This collaboration is expected to enhance SynAct Pharma’s visibility in the pharma and biotech industry, potentially impacting its market positioning and providing stakeholders with valuable insights into its operations.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company that focuses on resolving inflammation through the selective activation of the melanocortin system. The company offers a broad portfolio of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation resolution activity, aiding patients in achieving immune balance.
Average Trading Volume: 174,485
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.18B
For an in-depth examination of SYNACT stock, go to TipRanks’ Overview page.